Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 65,000 Class A shares on 04/03/2024, with an aggregate market value of $574,600. The shares to be sold were acquired through various means, including founders shares received on 09/01/2016, restricted stock vesting on 05/15/2023, and stock option exercises on 06/07/2023 and 07/12/2023. The securities were originally acquired as compensation or through cash payments. This planned sale follows a series of transactions over the past three months, where a total of 230,444 shares were sold for gross proceeds of $2,351,497.24. The notice of the upcoming sale was given in accordance with a plan adopted on 12/27/2023.

Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 65,000 Class A shares on 04/03/2024, with an aggregate market value of $574,600. The shares to be sold were acquired through various means, including founders shares received on 09/01/2016, restricted stock vesting on 05/15/2023, and stock option exercises on 06/07/2023 and 07/12/2023. The securities were originally acquired as compensation or through cash payments. This planned sale follows a series of transactions over the past three months, where a total of 230,444 shares were sold for gross proceeds of $2,351,497.24. The notice of the upcoming sale was given in accordance with a plan adopted on 12/27/2023.